4//SEC Filing
Cline Christopher R. 4
Accession 0001415889-25-012061
CIK 0001438533other
Filed
May 4, 8:00 PM ET
Accepted
May 5, 9:54 PM ET
Size
9.8 KB
Accession
0001415889-25-012061
Insider Transaction Report
Form 4
Cline Christopher R.
CHIEF FINANCIAL OFFICER
Transactions
- Sale
Common Stock
2025-05-05$21.05/sh−1,784$37,553→ 93,126 total - Exercise/Conversion
Performance-based restricted stock units
2025-05-02−4,920→ 4,920 total→ Common Stock (4,920 underlying) - Exercise/Conversion
Common Stock
2025-05-02+4,920→ 94,910 total
Footnotes (3)
- [F1]On September 1, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.
- [F2]Each PSU represents a contingent right to receive one share of the Common Stock of the Issuer.
- [F3]Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001943192
Filing Metadata
- Form type
- 4
- Filed
- May 4, 8:00 PM ET
- Accepted
- May 5, 9:54 PM ET
- Size
- 9.8 KB